The only Grade 4 TEAEs experienced by more than one patient in any cohort were increased gamma-glutamyl transpeptidase (GGT) (12.2%), neutropenia (6.1%), and decreased platelet count (4.1%), and all of these events occurred in biliary tract cancer patients. The gene discussed is GGTLC1; the disease is neutropenia.